Page 1

IЯRAS IRRAS AB ( PUBL ) YEAR - END REPORT JANUARY - DECEMBER 2020 Growth despite COVID - 19 resurgence Fourth quarter , October - December 2020 • Net revenue amounted to SEK 2.5 million ( 3.4 ) . • Operating loss ( EBIT ) amounted to SEK -36.8 million ( -35.7 ) . • Loss after tax amounted to SEK -38.1 million ( -36.5 ) . • Earnings per share before and after dilution amounted to SEK -0.57 ( -1.27 ) . Key accomplishments Agreement for Hummingbird signed with purchasing network Premier • Collaboration agreement signed with Karolinska University Hospital • IRRAflow launched in the Netherlands , Latin America and South Eastern Europe through distributors • Evaluation agreements signed with hospitals in the US , Denmark and Germany and multiple evaluations in the US completed with positive outlook • The company's first FDA quality audit performed without remarks • Transition to inhouse manufacturing of IRRAflow for improved quality and reduced cost The Board of Directors proposes no dividend Key figures Net revenue , SEK million Gross margin , % Operating loss ( EBIT ) , SEK million EBIT margin , % Loss after tax EBITDA , SEK million EBITDA margin , % Return on equity , % Period January - December 2020 • Net revenue amounted to SEK 7.4 million ( 5.3 ) . ● Operating loss ( EBIT ) amounted to SEK -134.3 million ( -151.5 ) . • Loss after tax amounted to SEK -135.9 million ( -151.1 ) . ● Earnings per share before and after dilution amounted to SEK -2.46 ( -5.61 ) . Key accomplishments after the end of the quarter • Patient treatments started at multiple hospitals in the US , where personnel have been trained during 2020 • Additional evaluation agreements signed in the US Oct - Dec 2020 2.5 Neg -36.8 Neg -38.1 -32.4 Neg Neg Oct - Dec 2019 3.4 Neg -35.7 Neg -36.5 -32.0 Neg Neg Jan - Dec 2020 7.4 Neg -134.3 Neg -135.9 -118.0 Neg Neg Jan - Dec 2019 5.3 Neg -151.5 Neg -151.1 -138.9 Neg Neg IRRAS AB INTERIM REPORT JANUARY - DECEMBER 2020 1